Error in Introduction [0.03%]
序言中的错误
Published Erratum
JAMA ophthalmology. 2023 Jun 1;141(6):611. DOI:10.1001/jamaophthalmol.2023.2622 2023
Manish Bhagat,Deepak Ghimire
Manish Bhagat
Harsha Bhattacharjee,Sakshi Mishra,Mohit Garg
Harsha Bhattacharjee
Unilateral Conjunctivitis With Multifocal Granulomatous Lesions in a Child Aged 10 Years [0.03%]
一名10岁患儿的单眼结膜炎伴有多灶性肉芽肿病变
Samantha M Arsenault,Erica Luse,Eric J Kim
Samantha M Arsenault
Rapid Anterior Capsular Phimosis in a Patient Without Risk Factors for Anterior Capsule Contraction Syndrome [0.03%]
无前囊收缩综合征危险因素患者的快速前囊膜菲薄症
Rinu George,Maya Jayarajan,Premanand Chandran
Rinu George
Artificial Intelligence for Visual Acuity-Gaps From Algorithm to Actualization [0.03%]
从算法到实现：用于视力敏锐度的人工智能研究缺口
Sally L Baxter,Judy E Kim
Sally L Baxter
Accuracy of Artificial Intelligence in Estimating Best-Corrected Visual Acuity From Fundus Photographs in Eyes With Diabetic Macular Edema [0.03%]
人工智能通过眼底照片估算糖尿病黄斑水肿患者最佳矫正视力的准确性
William Paul,Philippe Burlina,Rohita Mocharla et al.
William Paul et al.
Importance: Best-corrected visual acuity (BCVA) is a measure used to manage diabetic macular edema (DME), sometimes suggesting development of DME or consideration of initiating, repeating, withholding, or resuming treatme...
Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial [0.03%]
阿尼伯珠单抗生物类似药SB15治疗新生血管性年龄相关性黄斑变性的有效性和安全性：Ⅲ期随机临床试验
Se Joon Woo,Mario Bradvica,Attila Vajas et al.
Se Joon Woo et al.
Importance: Aflibercept biosimilars can expand available treatment options in retinal diseases and have the potential to improve patient access to safe and effective therapy. ...
Error in Author Name [0.03%]
作者姓名错误
Published Erratum
JAMA ophthalmology. 2023 Jul 1;141(7):697. DOI:10.1001/jamaophthalmol.2023.2675 2023
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial [0.03%]
儿童低浓度阿托品治疗三年有效性和安全性的随机临床试验：0.01%和0.02%阿托品的疗效及安全性比较研究
Karla Zadnik,Erica Schulman,Ian Flitcroft et al.
Karla Zadnik et al.
Importance: The global prevalence of myopia is predicted to approach 50% by 2050, increasing the risk of visual impairment later in life. No pharmacologic therapy is approved for treating childhood myopia progression. ...